Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Sponsor
Hospital Regional de Alta Especialidad del Bajio
Study ID
NCT05595447
Phase
PHASE2/PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
15 Years - 90 Years
Healthy Volunteers
Accepted

Interventions

  • Brentuximab Vedotin 50 MG [Adcetris] — DRUG
    Brentuximab plus blocked PD-1 plus ASCT plus maintenance Brentuximab plus blocked PD-1

Study Details

The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT. What is the progression-free survival and rate of metabolic responses complete in patients with high-risk R/R HL with the treatment strategy: BV+ PD-1 blockade consolidation with Auto-HSCT and maintenance with BV + PD-blockade 1?

Key Dates

First listed
Oct 27, 2022
Start date
Oct 18, 2022
Status verified
Dec 2024
Primary completion
Oct 18, 2025
Completion
Oct 18, 2025

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Brentuximab plus PD-1 blocked plus ASCT plus maintenance Brentuximab plus PD-1
    Brentuximab plus PD-1 blocked x 8 cycles plus ASCT plus maintenance Brentuximab plus PD-1 x 8 cycles

Primary Outcome Measure

Progression free survival [ Time Frame: 24 months ]

Central Contacts

Related Studies